Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disease-modification with aflibercept in advanced diabetic retinopathy (pilot)
2017-003193-14Phase 2Terminated
- Sponsor
- Department of Ophthalmology, Medical University of Vienna
- Start
- Aug 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aflibercept in proliferative diabetic retinopathy (PDR), sponsored by Department of Ophthalmology, Medical University of Vienna. Primary endpoint: Improvement in diabetic retinopathy severity score (DRSS). Started Aug 2017; status: terminated.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2017-003193-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003193-14.